The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.
about
Drug repositioning for enzyme modulator based on human metabolite-likeness.3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages.Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity.Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IL-33-induced cytokine production in primary mouse mast cells.
P2860
The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The efficacy of the ribonucleo ...... in preclinical models of AML.
@ast
The efficacy of the ribonucleo ...... in preclinical models of AML.
@en
The efficacy of the ribonucleo ...... in preclinical models of AML.
@nl
type
label
The efficacy of the ribonucleo ...... in preclinical models of AML.
@ast
The efficacy of the ribonucleo ...... in preclinical models of AML.
@en
The efficacy of the ribonucleo ...... in preclinical models of AML.
@nl
prefLabel
The efficacy of the ribonucleo ...... in preclinical models of AML.
@ast
The efficacy of the ribonucleo ...... in preclinical models of AML.
@en
The efficacy of the ribonucleo ...... in preclinical models of AML.
@nl
P2093
P2860
P1433
P1476
The efficacy of the ribonucleo ...... in preclinical models of AML.
@en
P2093
David L Caudell
Guerry J Cook
Howard L Elford
P2860
P304
P356
10.1371/JOURNAL.PONE.0112619
P407
P577
2014-11-17T00:00:00Z